AMPH Stock Analysis: Amphastar P | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 960m USD | 12M Return: -16.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 11.7M
EPS Trend: 2.6%
Qual. Beats: -2
Rev. Trend: 79.3%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Amphastar Pharmaceuticals is a U.S.-based bio-pharmaceutical company founded in 1996 and headquartered in Rancho Cucamonga, California, that develops, manufactures, markets, and sells both generic and proprietary injectable, inhalation, and intranasal products, with operations in the United States, China, and France. Its portfolio spans a diverse range of therapeutic areas, including emergency care (BAQSIMI for severe hypoglycemia, naloxone products for opioid overdose, epinephrine injection, and various emergency syringe products), respiratory health (Primatene MIST, Albuterol sulfate, Ipratropium Bromide HFA), anticoagulation (Enoxaparin), anesthesia (lidocaine products), diagnostics (Cortrosyn), and supportive care (Iron sucrose, Phytonadione, Teriparatide). The company also produces active pharmaceutical ingredients (APIs), including recombinant human insulin and porcine insulin.
Amphastar operates a hybrid business model that combines low-margin generic injectable competition with higher-margin proprietary and 505(b)(2)-type specialty products, a structure common among small-cap specialty pharma companies seeking to balance regulatory and pricing risk. Its vertical integration into API manufacturing, particularly insulin, distinguishes it from peers that rely solely on third-party suppliers and helps mitigate supply chain volatility in the generic sterile injectable market.
- BAQSIMI faces intensifying competition from rival glucagon nasal sprays
- FDA approvals of complex generic injectables drive segment revenue growth
- Enoxaparin generic pricing pressure compresses injectable product margins
| Net Income: 79.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -1.04 > 1.0 |
| NWC/Revenue: 65.12% < 20% (prev 53.40%; Δ 11.72% < -1%) |
| CFO/TA 0.10 > 3% & CFO 168.9m > Net Income 79.2m |
| Net Debt (466.9m) to EBITDA (191.4m): 2.44 < 3 |
| Current Ratio: 3.85 > 1.5 & < 3 |
| Outstanding Shares: last quarter (46.5m) vs 12m ago -6.88% < -2% |
| Gross Margin: 47.34% > 18% (prev 50.67%; Δ -3.33% > 0.5%) |
| Asset Turnover: 44.01% > 50% (prev 44.78%; Δ -0.77% > 0%) |
| Interest Coverage Ratio: 4.99 > 6 (EBIT TTM 128.6m / Interest Expense TTM 25.7m) |
| A: 0.28 (Total Current Assets 633.7m - Total Current Liabilities 164.5m) / Total Assets 1.65b |
| B: 0.41 (Retained Earnings 673.3m / Total Assets 1.65b) |
| C: 0.08 (EBIT TTM 128.6m / Avg Total Assets 1.64b) |
| D: 0.88 (Book Value of Equity 773.4m / Total Liabilities 874.8m) |
| Altman-Z'' = 4.66 = AA |
| DSRI: 1.03 (Receivables 147.8m/145.4m, Revenue 720.5m/728.3m) |
| GMI: 1.07 (GM 50.67% / 47.34%) |
| AQI: 0.92 (AQ_t 0.39 / AQ_t-1 0.42) |
| SGI: 0.99 (Revenue 720.5m / 728.3m) |
| TATA: -0.05 (NI 79.2m - CFO 168.9m) / TA 1.65b) |
| Beneish M = -3.00 (Cap -4..+1) = AA |
As of July 04, 2026, the stock is trading at USD 19.64 with a total of 315,753 shares traded. Over the past week, the price has changed by -6.65%, over one month by +6.45%, over three months by -3.96% and over the past year by -16.71%.
Current recommended Stop Loss: 18.40 (which is 6.3% or 1.3 ATR below the current price).
Amphastar P has received a consensus analysts rating of 3.67. Therefore, it is recommended to hold AMPH.
- StrongBuy: 2
- Buy: 0
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 22.8 | 16.2% |
P/E Trailing = 13.1205
P/S = 1.3328
P/B = 1.2417
P/EG = 2.77
Revenue TTM = 720.5m USD
EBIT TTM = 128.6m USD
EBITDA TTM = 191.4m USD
Long Term Debt = 609.8m USD (from longTermDebt, last quarter)
Short Term Debt = 11.4m USD (from shortTermDebt, last quarter)
Debt = 761.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 74.9m
Net Debt = 466.9m USD (calculated: Debt 761.3m - CCE 294.4m)
Enterprise Value = 1.43b USD (960.3m + Debt 761.3m - CCE 294.4m)
Interest Coverage Ratio = 4.99 (Ebit TTM 128.6m / Interest Expense TTM 25.7m)
EV/FCF = 10.56x (Enterprise Value 1.43b / FCF TTM 135.2m)
FCF Yield = 9.47% (FCF TTM 135.2m / Enterprise Value 1.43b)
FCF Margin = 18.76% (FCF TTM 135.2m / Revenue TTM 720.5m)
Net Margin = 11.00% (Net Income TTM 79.2m / Revenue TTM 720.5m)
Gross Margin = 47.34% ((Revenue TTM 720.5m - Cost of Revenue TTM 379.4m) / Revenue TTM)
Gross Margin QoQ = 41.08% (prev 46.79%)
Tobins Q-Ratio = 0.87 (Enterprise Value 1.43b / Total Assets 1.65b)
Interest Expense / Debt = 3.38% (Interest Expense 25.7m / Debt 761.3m)
Taxrate = 22.94% (23.6m / 102.8m)
NOPAT = 99.1m (EBIT 128.6m * (1 - 22.94%))
Current Ratio = 3.85 (Total Current Assets 633.7m / Total Current Liabilities 164.5m)
Debt / Equity = 0.98 (Debt 761.3m / totalStockholderEquity, last quarter 773.4m)
Debt / EBITDA = 2.44 (Net Debt 466.9m / EBITDA 191.4m)
Debt / FCF = 3.45 (Net Debt 466.9m / FCF TTM 135.2m)
Total Stockholder Equity = 774.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.84% (Net Income 79.2m / Total Assets 1.65b)
RoE = 10.23% (Net Income TTM 79.2m / Total Stockholder Equity 774.1m)
RoCE = 9.29% (EBIT 128.6m / Capital Employed (Equity 774.1m + L.T.Debt 609.8m))
RoIC = 6.79% (NOPAT 99.1m / Invested Capital 1.46b)
WACC = 6.74% (E(960.3m)/V(1.72b) * Re(10.01%) + D(761.3m)/V(1.72b) * Rd(3.38%) * (1-Tc(0.23)))
Discount Rate = 10.01% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -91.11 | Cagr: -5.70%
[DCF] Terminal Value 73.96% ; FCFF base≈141.2m ; Y1≈129.9m ; Y5≈115.4m
[DCF] Fair Price = 30.92 (EV 1.83b - Net Debt 466.9m = Equity 1.36b / Shares 44.1m; r=8.35% [WACC [floored]]; 5y FCF grow -10.01% → 2.50% )
EPS Correlation: 2.65 | EPS CAGR: 0.45% | SUE: -2.05 | # QB: -2
Revenue Correlation: 79.35 | Revenue CAGR: 8.71% | SUE: -0.36 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.81 | Chg30d=-12.64% | Revisions=-64% | Analysts=7
EPS current Year (2026-12-31): EPS=2.68 | Chg30d=-17.51% | Revisions=-64% | GrowthEPS=-17.5% | GrowthRev=+3.7%
EPS next Year (2027-12-31): EPS=3.14 | Chg30d=-9.28% | Revisions=-45% | GrowthEPS=+17.2% | GrowthRev=+5.6%
[Analyst] Revisions Ratio: -64%